The Impact of CRISPR/Cas9 Technology on Cardiac Research: From Disease Modelling to Therapeutic Approaches

• Published in: Stem cells international Vol. 2017; no. 2017; pp. 1 - 13
• Main Authors: Rossini, Alessandra, Hicks, Andrew A., Pramstaller, Peter P., Motta, Benedetta M.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Adaptability; Analysis; Biomedical materials; Cardiovascular disease; Cardiovascular diseases; Coronary artery disease; CRISPR; Deoxyribonucleic acid; DNA; Editing; Electrophysiology; Ethics; Gene mutations; Gene therapy; Genes; Genetic modification; Genetically modified organisms; Genome editing; Genomes; Genomics; Health aspects; Heart; Heart diseases; Heredity; Lipid metabolism; Medical research; Medicine, Experimental; Metabolism; Methods; Mutation; Pluripotency; Researchers; Review; Stem cells; Studies; Vectors (Biology); Viruses
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2017/8960236

Genome-editing technology has emerged as a powerful method that enables the generation of genetically modified cells and organisms necessary to elucidate gene function and mechanisms of human diseases. The clustered regularly interspaced short palindromic repeats- (CRISPR-) associated 9 (Cas9) system has rapidly become one of the most popular approaches for genome editing in basic biomedical research over recent years because of its simplicity and adaptability. CRISPR/Cas9 genome editing has been used to correct DNA mutations ranging from a single base pair to large deletions in both in vitro and in vivo model systems. CRISPR/Cas9 has been used to increase the understanding of many aspects of cardiovascular disorders, including lipid metabolism, electrophysiology and genetic inheritance. The CRISPR/Cas9 technology has been proven to be effective in creating gene knockout (KO) or knockin in human cells and is particularly useful for editing induced pluripotent stem cells (iPSCs). Despite these progresses, some biological, technical, and ethical issues are limiting the therapeutic potential of genome editing in cardiovascular diseases. This review will focus on various applications of CRISPR/Cas9 genome editing in the cardiovascular field, for both disease research and the prospect of in vivo genome-editing therapies in the future.